Genenta Science S.p.A. (GNTA) surged 84.52 percent to $5.96, up $2.73 on Friday, after the immuno-oncology company announced an expanded strategic collaboration with Anemocyte to advance an off-the-shelf lentiviral vector plasmid DNA technology platform.
The stock traded between $5.68 and $10.00 during the session after opening at $9.88, compared with a previous close of $3.23 on the Nasdaq. Trading volume soared to 19.24 million shares, far exceeding the average of 0.01 million.
Over the past 52 weeks, Genenta shares have traded between $2.56 and $10.00.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.